As malignant tumours are composed of heterogeneous cells varying in their degree of differentiation or malignancy, and as increased motility and invasiveness define more highly malignant tumour cell subsets, we studied the contribution of FPR to the invasive capacity of human GBM cells. This evidence concerns the gene FPR1 and glioblastoma.